AI

OBESITY and SARCOPENIA

BODY COMPOSITION

When conducting an obesity trial to measure body composition, it’s important to choose imaging options that provide accurate and reliable results. Here are some of the best imaging modalities commonly used for this purpose:

  • Dual-Energy X-ray Absorptiometry (DXA): DXA scans are highly accurate and are considered the gold standard for measuring body composition. They can provide information about bone density, fat mass, and lean mass.
  • Computed Tomography (CT) Scan: CT scans can offer detailed information about fat distribution within the body, allowing for precise measurements of visceral and subcutaneous fat.
  • Magnetic Resonance Imaging (MRI): MRI can provide excellent visualization of fat and lean tissue, offering insights into body composition. It’s non-invasive and does not involve radiation.
  • Bioelectrical Impedance Analysis (BIA): While not an imaging modality in the traditional sense, BIA uses electrical impedance to estimate body composition. It’s relatively simple and cost-effective.
  • Ultrasound: Ultrasound imaging can be used to assess the subcutaneous fat thickness and muscle thickness at specific locations, making it useful for localized body composition measurements.
  • Air Displacement Plethysmography (ADP): ADP, commonly measured using the BodPod, calculates body composition based on the principles of air displacement. It’s non-invasive and provides accurate results.
  • Positron Emission Tomography (PET) Scan: PET scans can be used to assess metabolic activity in fat tissue, providing insights into obesity-related metabolic changes.

The choice of imaging modality should depend on factors such as the specific research goals, budget, and accessibility of equipment. It’s often advisable to consult with a medical imaging expert or radiologist to determine the most suitable option for your obesity trial. Additionally, consider ethical and safety aspects when conducting imaging studies involving human participants

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • Eligibility and Safety Assessments
  • Body Mass Index (BMI) Score
  • Visceral Adiposity Index (VAI)
  • Fat Mass Index (FMI)
  • Fat-Free Mass Index (FFMI)
  • Total Body Fat Percentage
  • Sarcopenia Index
  • Epicardial Fat Volume Score
  • Liver Fat Score
  • Muscle Quality Score
  • Phase Angle (PhA)
Experience: Imaging
  • MRI
  • DEXA
  • CT
  • PET, PET-CT
  • Ultrasound
  • ADP
  • BIA
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.

Supportting Advance Imaging Research in Women’s Reproductive Health

Supportting Advance Imaging Research in Women’s Reproductive Health

Ferring Pharmaceuticals and Image Analysis Group Collaborate to Advance Research in the complex field of pregnancy.

London, UK — Image Analysis Group, a leader in medical imaging, have joined forces in a strategic collaboration with Ferring Pharmaceuticals to advance Women’s Reproductive Health through AI-driven medical image analysis.

Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals, stated, “Our collaboration with IAG is a testament to our commitment to AI-driven research in the complex field of pregnancy.”

Dr. Olga Kubassova, CEO of IAG, added, “We are excited to support the Ferring team in leveraging AI to gain deeper insights into women’s reproductive health, ultimately aiming to enhance the chances of a healthy pregnancy for women globally.”

IAG’s mission is to assist pharmaceutical partners in efficiently developing transformative medicines. This is achieved through their expertise in medical imaging and AI, utilizing their proprietary platform, DYNAMIKA. This platform is designed to efficiently manage large volumes of imaging data in multi-centre trials and incorporates integrated AI modules. The partnership promises innovative approaches to improve women’s health worldwide.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group is a leading advanced medical imaging research and analysis services provider. With a focus on precision and scientific rigour, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

READ NEXT CASE STUDY >